Navigation Links
Study Disproves Belief That Hepatitis C Blunts HIV Drugs
Date:7/25/2008

Impaired immune response after antiretroviral therapy may be due to genetic factors

FRIDAY, July 25 (HealthDay News) -- A new study challenges the long-held belief that the hepatitis C virus (HCV) impairs the immune system's ability to restore itself after HIV patients are treated with highly active antiretroviral therapy (HAART).

From 50 percent to 90 percent of HIV-infected drug users are also infected with HCV. Intravenous drug use is the main cause of both types of infection.

Researchers at Wake Forest University Baptist Medical Center focused on levels of CD4 cells -- the immune cells that are attacked by HIV -- and whether CD4 cells can rebuild after HAART is used to suppress HIV infection. For the study, the researchers analyzed the medical records of 322 patients.

"We've been observing that in some patients that are co-infected with hepatitis C, we were treating their HIV with HAART but didn't always get very good restoration of CD4," lead researcher Dr. Marina Nunez, an assistant professor of infectious diseases, said in a Wake Forest news release. "Some studies have suggested it was because of the hepatitis C. This study says it's not the presence of active hepatitis C replication."

She said impaired immune restoration seen in some HIV/HCV-infected patients after HAART may be due to a number of other causes, such as genetic factors involved in immune system regulation, confounding factors associated with HCV acquisition, or other unknown factors.

"Research efforts should pursue the role of those other factors in the immune restoration," Nunez said.

"From a clinical standpoint, although these findings will not alter the clinical management of HIV-HCV-co-infected patients, they make clear that even after successful treatment of the HCV infection, some patients may not get an adequate CD4 recovery under HIV treatment," she said.

The study was published in the July issue of AIDS Research and Human Retroviruses.

More information

The U.S. National Institute of Allergy and Infectious Diseases has more about HIV treatment.



-- Robert Preidt



SOURCE: Wake Forest University Baptist Medical Center, news release, July 25, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... Datos Health , ... partnership with Med-e-Mass , the largest Electronic Medical Records (EMR) provider in South ... care plan incentives to a patient’s remote health progress, empowering the patient to take ...
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility may be ... conditions and has helped many women become pregnant upon treating their diagnosis. ... and simple outpatient evaluations. We can provide the necessary information to diagnose ...
(Date:4/26/2017)... ... April 26, 2017 , ... Want to learn more about ... ) that demonstrates how this advanced plant breeding technology is a more efficient ... fewer resources. It highlights the business’ principles, research and collaboration efforts in this ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... is proud to announce that it has received 510(k) clearance from the U.S. ... Home and the MyoCycle Pro. , Both devices are stationary cycling systems that ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... have signed an agreement to be the preferred physical therapy provider for Derby ... returning them to Derby City CrossFit as quickly and effectively as possible, ProRehab’s ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research and ... Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 Mn ... by 2024, expanding at a CAGR of 5.6% from 2016 ...
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)... 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the ... Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Chief Executive Officer of the Company is scheduled to present on ... Bear and the Chairman of the Board, Tony Holler ... ...
Breaking Medicine Technology: